UV-B irradiation attenuates dermal effects of botulinum toxin A: A randomized, double-blind, placebo-controlled study

Dermatologic Surgery

Volumn 33, Issue SUPPL. 1, 2007, Pages

  Sycha, Thomas ^a   Kotzailias, Nicole ^a   Kranz, Gottfried ^a   Trautinger, Franz ^b   Schnider, Peter ^c   Auff, Eduard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ANHIDROSIS; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUNBURN; SWEATING; ULTRAVIOLET B RADIATION;

ADULT; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; ULTRAVIOLET RAYS;

EID: 33846009124     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2006.32338.x     Document Type: Article

References (22)

1. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004;51:223-33.
2. Carruthers JA, Lowe NJ,Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840-9.
3. Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997;136:548-52.
4. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001;323:596-9.
5. Heckmann M, Ceballos-Baumann AO, Plewig G, Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001;344:488-93.
6. Habbema L. Facial esthetics and patient selection. Clin Dermatol 2004;22:14-7.
7. Dayan SH, Bassichis BA. Evaluation of the patient for cosmetic Botox injections. Facial Plast Surg Clin North Am 2003;11:349-58.
8. Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol 2004;22:34-9.
9. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2004;22:66-75.
10. Carruthers J, Fagien S, Matarasso SL, Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Recontr Surg 2004;114:(Suppl):1S.
11. Gustorff B, Anzenhofer S, Sycha T, et al. The sunburn pain model: the stability of primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesth Analg 2004;98:173-7.
12. Minor V. Ein neues Verfahren zur klinischen Untersuchung der Schweissabsonderung. Z Neurologie 1927;101:302-8.
13. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
14. Erbguth F. Dose-dependent anhidrotic effect of botulinum toxin. Curr Probl Dermatol 2002;30:131-40.
15. Schlereth T, Mouka I, Eisenbarth G, et al. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations. Auton Neurosci 2005;117:120-6.
16. Krämer HH, Angerer C, Erbguth F, et al. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003;250:188-93.
17. Schnider P, Binder M, Berger T, Auff E. Botulinum A toxin injection in focal hyperhidrosis. Br J Dermatol 1996;134:1160.
18. Wollina U, Karamfilov T, Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 2002;46:536-40.
19. Trautinger F. Photobiology-basic principles. In: Demis DJ, Burgdorf WH, Raimer SS, et al., editors. Clinical dermatology, 26th ed, revision. Philadelphia: Lipincott-Raven, 1999:p. 1-12.
20. Peus D, Pittelkow MR. Reactive oxygen species as mediators of UVB-induced mitogen-activated protein kinase activation in keratinocytes. Curr Probl Dermatol 2001;29:114-27.
21. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003;25:207-18.
22. Clydesdale GJ, Dandie GW, Muller HK. Ultraviolet light induced injury: immunological and inflammatory effects. Immunol Cell Biol 2001;79:547-68.